Wedbush Reiterates Outperform on Nuvation Bio, Maintains $11 Price Target

Benzinga · 1d ago
Wedbush analyst David Nierengarten reiterates Nuvation Bio (NYSE:NUVB) with a Outperform and maintains $11 price target.